Christine Bellanné-Chantelot, PharmD, PhD; Dominique Chauveau, MD; Jean-François Gautier, MD, PhD; Danièle Dubois-Laforgue, MD, PhD; Séverine Clauin; Sandrine Beaufils; Jean-Marie Wilhelm, MD; Christian Boitard, MD; Laure-Hélène Noël, MD; Gilberto Velho, MD, PhD; José Timsit, MD
Acknowledgments: The authors thank the families for their participation in the study; Drs. Véronique Baudouin, Véronique Blanchetier, Guy Parlier, and Rémi Salomon for the follow-up of patients; and Dr. Pascal Hammel for helpful advice.
Potential Financial Conflicts of Interest: None disclosed.
Requests for Single Reprints: Christine Bellanné-Chantelot, PharmD, PhD, Fédération des Services de Biochimie, Laboratoire de Biologie Moléculaire, Hôpital Saint-Antoine, 184 rue du faubourg Saint-Antoine, 75012 Paris, France; e-mail, firstname.lastname@example.org.
Current Author Addresses: Dr. Bellanné-Chantelot, Ms. Clauin, and Ms. Beaufils: Fédération des Services de Biochimie, Laboratoire de Biologie Moléculaire, Hôpital Saint-Antoine, 184 rue du Faubourg Saint-Antoine, 75012 Paris, France.
Drs. Chauveau and Noël: Service de Néphrologie, Hôpital Necker, 161 rue de Sèvres, 75015 Paris, France.
Dr. Gautier: Service d'Endocrinologie, Hôpital Saint-Louis, 1 Avenue Claude Vellefaux, 75010 Paris, France.
Drs. Dubois-Laforgue, Boitard, and Timsit: Service d'Immuno-Diabétologie, Hôpital Cochin, 27 rue du Faubourg Saint-Jacques, 75014 Paris, France.
Dr. Wilhelm: Centre Hospitalier Saint-Morand, BP 1022, 68134 Altkirch Cedex, France.
Dr. Velho: INSERM U561, Hôpital Saint-Vincent-de-Paul, 74 Avenue Denfert Rochereau, 75014, Paris, France.
Author Contributions: Conception and design: C. Bellanné-Chantelot, D. Chauveau, G. Velho, J. Timsit.
Analysis and interpretation of the data: C. Bellanné-Chantelot, D. Chauveau, J.-F. Gautier, D. Dubois-Laforgue, S. Clauin, S. Beaufils, J.-M. Wilhelm, C. Boitard, L.-H. Noël, G. Velho, J. Timsit.
Drafting of the article: C. Bellanné-Chantelot, D. Chauveau, G. Velho, J. Timsit.
Critical revision of the article for important intellectual content: C. Bellanné-Chantelot, D. Chauveau, J.-F. Gautier, D. Dubois-Laforgue, C. Boitard, G. Velho, J. Timsit.
Final approval of the article: C. Bellanné-Chantelot, D. Chauveau, J.-F. Gautier, D. Dubois-Laforgue, S. Clauin, S. Beaufils, J.-M. Wilhelm, C. Boitard, L.-H. Noël, G. Velho, J. Timsit.
Provision of study materials or patients: D. Chauveau, J.-F. Gautier, D. Dubois-Laforgue, J.-M. Wilhelm, C. Boitard, J. Timsit.
Administrative, technical, or logistic support: S. Clauin, S. Beaufils.
Collection and assembly of data: C. Bellanné-Chantelot, D. Chauveau, J. Timsit.
Maturity-onset diabetes of the young type 5 (MODY5), a type of dominantly inherited diabetes mellitus and nephropathy, has been associated with mutations of the hepatocyte nuclear factor-1β (HNF-1β) gene, mostly generating truncated protein. Various phenotypes, including urogenital malformations, are related to HNF-1β mutations.
To describe clinical and genetic findings in 13 patients with 8 novel HNF-1β mutations.
Multicenter, descriptive study.
2 departments of diabetes, 1 department of internal medicine, and 1 department of nephrology.
8 probands with diabetes diagnosed before 40 years of age and nondiabetic kidney disease who were selected independent of their family history of diabetes, and 5 offspring.
Characteristics of diabetes, renal function and structure, genital tract abnormalities, pancreas structure, insulin secretion, exocrine pancreas function, and liver test results.
All mutations, including 5 missense changes, were found in the DNA-binding domain. Cosegregation of the mutation and MODY5 phenotype was observed in 4 families. Occurrence of a de novo mutation was demonstrated in 2 families. Diabetes was present in 10 of 13 mutation carriers. It was clinically overt in 5 participants and found by screening at age 19 to 38 years in 5 participants. Pancreas atrophy was observed in 5 of 6 probands, and pancreas exocrine insufficiency was observed in 6 of 7 probands. Renal involvement, consisting of structural changes and slowly progressive renal failure, was recognized in 9 patients at 18 to 41 years of age. Dysplastic kidneys were found by ultrasonography in 3 fetuses who subsequently showed transient neonatal renal failure. Genital tract abnormalities were present in 5 probands and liver enzyme levels were abnormal in 11 of 13 patients.
Since the study was small and not population-based, it could not estimate the prevalence of MODY5. Other phenotypes might be associated with HNF-1β mutations.
Maturity-onset diabetes of the young type 5 encompasses a wide clinical spectrum. Analysis for mutations of HNF-1β is warranted, even without a family history of diabetes, in nonobese patients with diabetes and slowly progressive nondiabetic nephropathy, particularly when pancreatic atrophy or genital abnormalities are present.
Learn more about subscription options.
Register Now for a free account.
Bellanné-Chantelot C, Chauveau D, Gautier J, Dubois-Laforgue D, Clauin S, Beaufils S, et al. Clinical Spectrum Associated with Hepatocyte Nuclear Factor-1β Mutations. Ann Intern Med. 2004;140:510–517. doi: 10.7326/0003-4819-140-7-200404060-00009
Download citation file:
Published: Ann Intern Med. 2004;140(7):510-517.
Cardiology, Coronary Risk Factors, Diabetes, Diabetic Nephropathy, Endocrine and Metabolism.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only